Business Wire

Yokogawa Launches OpreX(TM) Profit-driven Operation Solution to Enable Integrated Plant Performance Management

Jaa

Yokogawa Electric Corporation (TOKYO:6841) announces OpreX(TM) Profit-driven Operation, a solution for process industries that drives seamless alignment with plant management objectives across the organization, from the operations floor through to the C-suite. The solution is centered on a methodology of interrelated performance indicators distilled from Yokogawa’s extensive domain knowledge, and promotes profitability by helping to optimize the balance between conflicting objectives. It incorporates a new performance dashboard and related services designed specifically for the operations level, as well as programs provided by KBC Advanced Technologies, a wholly-owned Yokogawa subsidiary specializing in consulting and simulation for process industry management. The solution has already been optimized for oil refining and petrochemicals, and Yokogawa intends to expand its application to LNG and basic chemical plants in the near future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180606006497/en/

Conceptual framework of how operations, engineering, and top management synaptic performance indicat ...

Conceptual framework of how operations, engineering, and top management synaptic performance indicators (SPIs) examples are structured to align with high-level plant management objectives (Graphic: Business Wire)

“Process industry executives say that, despite considerable investment in IT, they don’t have true visibility into what is happening across their plants, and that objectives they communicate are not being clearly understood at the operations level,” said Satoru Kurosu, executive vice president, and head of Yokogawa’s Premium Solutions and Service Business Headquarters. “To help solve these critical issues, Yokogawa has constructed a cross-organizational performance metrics methodology to provide the visibility and alignment they need. The synergistic value that Yokogawa and KBC can deliver is matchless in the industry.”

Performance metrics methodology

This unique solution has been made possible by integrating Yokogawa’s expertise in industrial automation technologies with the extensive domain knowledge of experts at KBC, which has decades of global analysis and consulting experience with major energy and chemical plants. Yokogawa collaborated closely with KBC industry consultants to first define and then systematically structure several hundred metrics, which Yokogawa calls “synaptic performance indicators” (SPIs), that are collected at the plant operations, engineering, and top management levels in refinery operations, based on deep knowledge of how they affect plant performance.

Performance dashboard for operations

As part of the solution launch, Yokogawa is releasing a new performance dashboard and related services that are integrated into a CENTUM(TM) distributed control system* (DCS) to enable plant operators to monitor in real time how their operation patterns are impacting high-level plant management objectives. When the service is implemented at a plant, optimal setpoint ranges are determined for each SPI, and then if a certain indicator moves outside the ideal range, built-in expert advice is displayed to support prompt action by even inexperienced operators. The SPIs and operator performance data are automatically accumulated to enable internal and industry benchmarking, root cause analysis, and expert consulting for continuous profitability gains.

“Plant control systems continuously receive a vast amount of information from sensors and devices, but the utilization of this big data collected in real time by the DCS has mainly been limited to front-line plant safety and line control,” said Masatoshi Nakahara, Yokogawa executive vice president, and head of the IA Systems and Service Business Headquarters. “Bringing together the DCS big data and the captured knowledge of Yokogawa and KBC experts within the performance dashboard and services dramatically improves transparency, feedback, and motivation for operators, letting them transform their work from event-driven to being sustainably profit-driven.”

Cloud-based program for engineering and top management

The Profit-driven Operation solution portfolio also includes the KBC Co-Pilot Program(TM), a unique package of cloud-based service offerings that displays engineering and management-level SPIs, and remotely supports assets with domain expertise and insight. In connection with this program, other KBC consulting services such as Operational Excellence and Profit Improvement are available as required.

OpreX brand

Profit-driven Operation is the first solution to bear the OpreX brand, under which all of Yokogawa’s industrial automation products, services, and solutions will be unified moving forward. It is also a flagship solution representing Yokogawa’s Synaptic Business Automation(TM) concept, which underlies a process of co-innovation with customers to create sustainable value by connecting everything in their organization.

For more information

OpreX Profit-driven Operation website: https://www.yokogawa.com/solutions/solutions/pdo
OpreX brand website: https://www.yokogawa.com/oprex/

*Requires CENTUM VP R6 or later

About Yokogawa

Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 112 companies spanning 61 countries, generating US$3.8 billion in sales in FY2017. For more information, please visit www.yokogawa.com.

The names of corporations, organizations, and products herein are either trademarks or registered trademarks of their respective holders.

Contact information

Yokogawa Electric Corporation
Public Relations
Integrated Communications Center
Yokogawa-pr@cs.jp.yokogawa.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®20.5.2019 03:16:00 EESTTiedote

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019 Digestive Disease Week® (DDW) annual scientific meeting (May 18-21 in San Diego, CA), one of 18 Takeda sponsored vedolizumab abstracts accep

Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought19.5.2019 22:15:00 EESTTiedote

ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference. The study found significant differences in one-year adherence between people of different ages and disease severity levels: Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women. People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs. 70.4%). People with self-reported severe sleep apnea were 78% adherent at the one-year mark, compared to 70.5% of those with self-reported moderate sleep apnea, and 65.2% of those with mild sleep apnea. “Sleep specialists, pulmonologists, and primary care physicians should heed these results and ensure that their younger, female, and more mildly diagnosed patients have the proper supports to stay on therapy,” said Adam B

Workiva Named Best-In-Class Cloud Service Provider at UK Cloud Awards17.5.2019 15:00:00 EESTTiedote

Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, was named the Best-In-Class Cloud Service Provider by the UK Cloud Awards 2019 at a ceremony here last night. Now in its sixth year, the UK Cloud Awards recognise innovation and excellence in the cloud industry by showcasing leading companies, customers and individuals in the United Kingdom. Workiva was recognised for its Wdesk platform that helps organisations consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders. Workiva, the global leader in XBRL and Inline XBRL, is also streamlining how customers comply with the European Securities and Markets Authority's mandate for Inline XBRL for European Single Electronic Format (ESEF) reporting. More than 5,000 EU issuers will be required to use ESEF taxonomy for their annual financial reports, ending on or after Jan

Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 201917.5.2019 13:13:00 EESTTiedote

Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019. “This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.” Poste

WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology17.5.2019 12:38:00 EESTTiedote

The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019. ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers in Paris (France) on June 23-24, 2019 to discuss Innovation and Global Deployment of Precision Oncology. The current status of Precision Oncology across the globe will be examined with the exceptional participation of the chairmen of the event, Richard L. Schilsky, Chairman WIN Consortium(*), Senior Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero, Vice Chairman WIN Consortium, President of ESMO and Director of Vall d’Hebron Institute of Oncology, Spain. Global experience will be shared: Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA The Value of Personalized Medici

Corsearch Acquires Principium Trademark Watch and Domain Services Businesses17.5.2019 11:00:00 EESTTiedote

Corsearch, the global brand creation, clearance, and protection leader, is pleased to announce the acquisition of the Principium Strategies trademark watch and domain services businesses, the brand protection subsidiary of Ladas and Parry LLP, a leader in global intellectual property law. The acquisition is effective immediately, solidifying and expanding Corsearch’s full-service trademark solutions offering for clients and brands globally. Principium is Corsearch’s third acquisition since becoming a standalone company in January 2018. The acquisition brings Corsearch’s employee count to more than 350 operating in 28 locations worldwide and adds valuable industry expertise and additional capabilities to Corsearch. “This is another really exciting acquisition for our business and a step forward in the evolution of Corsearch,” said Stephen Stolfi, Chief Commercial Officer of Corsearch. “Principium has provided clients with industry-leading trademark watching services for over 80 years an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme